FIELD: chemistry.
SUBSTANCE: group of inventions relates to immunotherapy. Immune system stimulating micellar composition contains toll-like receptor 7 (TLR7) agonist of formula (IA), or its tautomer, or its pharmaceutically acceptable salt or solvate,
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) - polyethylene glycol (PEG) 2000, where the molar ratio of DSPE-PEG2000 and the TLR7 agonist is 95:5, 90:10 or 80:20. Also disclosed is a pharmaceutical composition for immunotherapy and use of the micellar composition or pharmaceutical composition for preventing, treating or relieving cancer.
EFFECT: group of inventions provides higher efficacy of the declared therapeutic compositions.
7 cl, 21 dwg, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEGYLATED LIPOSOMES AND THEIR APPLICATION METHODS | 2017 |
|
RU2796539C2 |
| COORDINATION COMPLEX OF PLATINUM (II) DIAMINOCYCLOHEXANE WITH BLOCK COPOLYMER CONTAINING POLYCARBOXYLIC ACID SEGMENT AND INCLUDING ANTICANCER AGENT | 2004 |
|
RU2335512C2 |
| NANO-ALUMINUM-PARTICLES CONTAINING SIZE-REGULATING AGENT | 2017 |
|
RU2753874C2 |
| PEGYLATED LIPOSOMES FOR IMMUNOUGEN-CODING RNA DELIVERY | 2012 |
|
RU2628705C2 |
| METHOD FOR TREATING CANCER BY TARGETING SUPPRESSOR CELLS OF MYELOID ORIGIN | 2017 |
|
RU2776899C2 |
| PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2690377C2 |
| LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF RNA ENCODING PROTEIN | 2011 |
|
RU2577983C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| CREATING CONTROLLED RELEASE PROFILE OF DRUG SUBSTANCE USING LIPOSOMAL COMPOSITION IN AQUEOUS AND ANHYDROUS SOLUTIONS | 2014 |
|
RU2712157C2 |
| COMPOSITIONS CONTAINING BIOLOGICAL AGENT | 1996 |
|
RU2166934C2 |
